As Sandoz waits for Novartis to determine its fate, the generics player buys out a respiratory device company
While Novartis chief Vas Narasimhan mulls whether or not the pharma will sell off Sandoz, the giant generics drug subsidiary is still trucking along like business as usual.
On Monday, the company acquired Coalesce Product Development Limited, a Cambridge, UK-based company focused on respiratory devices. Coalesce currently has three different types of inhalers in its pipeline.
Sandoz kept details close to the vest, announcing the acquisition in a brief statement and remaining mum on any financial specifics. A Sandoz spokesperson added in an email that while inhalers are certainly in scope for Sandoz, the overall scope is broader and goes beyond purely respiratory devices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
